Companies: 10,795·Total market cap: $144.5T
Arcus Biosciences, Inc.

Arcus Biosciences, Inc.

RCUSNYSEHealthcare● Active
$23.75
+$0.56(+2.41%)
Market Cap$2.4B
P/E Ratio
52W High$28.72
52W Low$7.91
SEC Filings

Arcus Biosciences, Inc. (RCUS) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001724521 · RCUS · NYSE · as of Jun 8, 2026

Filing snapshot

582
Total Filings
4
Latest Form
2026-06-01
Most Recent
2018
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001724521 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-02-25
Fiscal Year End
Feb 25, 2026
Accession No.
0001724521-26-000009
Primary Document
rcus-20251231.htm
Source: data.sec.gov · CIK 0001724521 · Accession 0001724521-26-000009

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-05
8-KCurrent Report
8-K
2026-05-05Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
10-QQuarterly Report
10-Q
2026-05-05
View
8-KCurrent Report
8-K
2026-05-05
View
ARSARS
ARS
2026-04-21
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-21
View
DEF 14AProxy Statement
DEF 14A
2026-04-21
View
8-KCurrent Report
8-K
2026-04-20
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-03-26
View
8-KCurrent Report
8-K
2026-03-23
View
S-3ASRS-3ASR
S-3ASR
2026-02-25
View
S-8Employee Stock Plan Registration
S-8
2026-02-25
View
10-KAnnual Report
10-K
2026-02-25
View
8-KCurrent Report
8-K
2026-02-25
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-01-08
View
8-KCurrent Report
8-K
2025-12-18
View
8-KCurrent Report
8-K
2025-12-12
View
Showing 1–15 of 286 filingsForm 4 / 144 hidden· 582 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001724521  |  Exchange: NYSE · Healthcare

Arcus Biosciences, Inc. (NYSE: RCUS) has submitted 582 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2018. As a Healthcare sector company with CIK 0001724521, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Arcus Biosciences, Inc.'s most comprehensive regulatory disclosure. The most recent Arcus Biosciences, Inc. 10-K was filed on 2026-02-25 for fiscal year ending 2026. Historical RCUS 10-K annual reports are available from 2017 through 2026.

Investors researching Arcus Biosciences, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08

Frequently Asked Questions

RCUS SEC Filings · 8 questions

Arcus Biosciences, Inc. (RCUS) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 582 filings and access original documents at no cost. Arcus Biosciences, Inc.'s CIK is 0001724521.

RCUS SEC filingsArcus Biosciences, Inc. SEC documentsfind RCUS 10-K